Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S

November 24, 2021 – announcement no. 14

At the Annual General Meeting of Chr. Hansen Holding A/S held on Wednesday November 24, 2021 the following proposals set out in the agenda were adopted:

- It was resolved to pay an ordinary dividend of DKK 6.54 per share of DKK 10.
- The advisory vote on the 2020/21 Remuneration Report.
- It was resolved to adjust the Board base fee and Board committee fees in 2021/22 as outlined in the notice convening the Annual General Meeting. The travel allowance for 2021/22 will be maintained at the same level as in 2020/21.
- It was resolved to approve the proposed indemnification arrangements and related amendment of the Company’s Remuneration Policy.
- Re-election of Dominique Reiniche as Chair of the Board of Directors.
- Re-election of Jesper Brandgaard, Luis Cantarell, Lise Kaæ, Heidi Kleinbach-Sauter, Kevin Lane and Lillie Li Valeur as members of the Board of Directors.
- Re-election of PwC Statsautoriseret Revisionspartnerselskab as auditor of the Company.
- Authorization of the Chair of the Annual General Meeting to file the resolutions passed with the Danish Business Authority and to make any such changes as the Danish Business Authority may require as a condition for registering or approving the resolutions passed.

For further information please contact:
Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364
Annika Stern, Senior Investor Relations Manager, Tel: +45 2399 2382
Yannick Vanderveeren, Head of Media Relations, Tel: +45 2068 6425

About Chr. Hansen

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable biotech company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.